Light Chain Bioscience - Novimmune SA
10
2
2
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
20.0%
2 terminated/withdrawn out of 10 trials
75.0%
-11.5% vs industry average
0%
0 trials in Phase 3/4
17%
1 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
A Study of NILK-2301 in Patients with Locally Advanced or Metastatic Low Tumor Volume (LTV) Colorectal Cancer
Role: lead
A Study of NI-1801 in Patients with Mesothelin Expressing Solid Cancers
Role: lead
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Emapalumab in Adult Patients With HLH
Role: collaborator
Study of an Anti-TLR4 mAb in Rheumatoid Arthritis
Role: lead
First in Human Study of an Anti-Toll-like Receptor 4 (TLR4) Monoclonal Antibody (NI-0101) in Adult Healthy Volunteers
Role: lead
Primary Biliary Cirrhosis: Investigating A New Treatment Option Using NI-0801, an Anti-CXCL10 Monoclonal Antibody
Role: lead
First in Human Study of NI-0701 in Healthy Volunteers
Role: lead
NI-0801 in Allergic Contact Dermatitis
Role: lead
NI-0401 in Patients With Acute Renal Allograft Rejection
Role: lead
NI-0401 in Active Crohn's Disease
Role: lead
All 10 trials loaded